A number of research firms have changed their ratings and price targets for Femasys (NASDAQ: FEMY):
- 11/16/2026 – Femasys was upgraded by Wall Street Zen from “strong sell” to “sell”.
- 11/13/2026 – Femasys had its “sell (e+)” rating reaffirmed by Weiss Ratings.
- 11/8/2026 – Femasys was downgraded by Wall Street Zen from “sell” to “strong sell”.
- 10/31/2026 – Femasys was downgraded by Wall Street Zen from “sell” to “strong sell”.
- 10/17/2026 – Femasys was upgraded by Wall Street Zen from “strong sell” to “sell”.
- 10/3/2026 – Femasys was downgraded by Wall Street Zen from “sell” to “strong sell”.
Femasys Stock Performance
Shares of NASDAQ FEMY traded down $0.02 during midday trading on Friday, hitting $1.24. The company’s stock had a trading volume of 95,627 shares, compared to its average volume of 248,697. The stock has a fifty day moving average price of $1.83 and a 200 day moving average price of $5.42. Femasys Inc. has a one year low of $1.07 and a one year high of $20.80. The company has a current ratio of 8.67, a quick ratio of 0.55 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $10.74 million, a price-to-earnings ratio of -0.60 and a beta of -2.13.
Femasys (NASDAQ:FEMY – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.07. Femasys had a negative net margin of 640.76% and a negative return on equity of 114.48%. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.62 million.
Femasys Inc. is a medical technology company focused on developing and commercializing products for women’s health, with an emphasis on fertility and contraception. Founded in 2004 and headquartered in Georgia, the company aims to provide minimally invasive options for reproductive care. Its products include FemVue, a system used with ultrasound to evaluate whether a woman’s fallopian tubes are open, and FemaSeed, a device designed to deliver sperm closer to the site of fertilization during insemination.
Read More
- Five stocks we like better than Femasys
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for Femasys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys Inc and related companies with MarketBeat.com's FREE daily email newsletter.
